{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:54:43Z","timestamp":1762005283133,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41431-020-00721-9","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T11:11:05Z","timestamp":1600427465000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of agalsidase-\u03b2 administration on vascular function and blood pressure in familial Anderson\u2013Fabry disease"],"prefix":"10.1038","volume":"29","author":[{"given":"Cosimo Andrea","family":"Stamerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-3218","authenticated-orcid":false,"given":"Vanessa","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"d\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1005-4689","authenticated-orcid":false,"given":"Davide","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"721_CR1","doi-asserted-by":"publisher","unstructured":"Granzotto A, Bomba M, Castelli V, Navarra R, Massetti N, d\u2019Aurora M, et al. Inhibition of de novo ceramide biosynthesis affects aging phenotype in an in vitro model of neuronal senescence. Aging. 2019;11. https:\/\/doi.org\/10.18632\/aging.102191.","DOI":"10.18632\/aging.102191"},{"key":"721_CR2","doi-asserted-by":"publisher","unstructured":"Miller JJ, Aoki K, Moehring F, Murphy C, O\u2019Hara C, Tiemeyer M, et al. Neuropathic pain in a Fabry disease rat model. JCI Insight. 2018;3. https:\/\/doi.org\/10.1172\/jci.insight.99171.","DOI":"10.1172\/jci.insight.99171"},{"key":"721_CR3","doi-asserted-by":"crossref","unstructured":"Desnick RJ. Fabry disease. In: Rosenberg\u2019s molecular and genetic basis of neurologic and psychiatric disease. 5th Edition Elsevier; 2015. p. 419\u201330.","DOI":"10.1016\/B978-0-12-410529-4.00038-3"},{"key":"721_CR4","unstructured":"NCBI. https:\/\/www.ncbi.nlm.nih.gov\/nuccore. 2020."},{"key":"721_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/jhg.2012.32","volume":"57","author":"LT Tura\u00e7a","year":"2012","unstructured":"Tura\u00e7a LT, Pessoa JG, Motta FL, M\u00fcller KB, Louren\u00e7o CM, Marques WJ, et al. New mutations in the GLA gene in Brazilian families with Fabry disease. J Hum Genet. 2012;57:347\u201351.","journal-title":"J Hum Genet"},{"key":"721_CR6","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","volume":"50","author":"KE Crutchfield","year":"1998","unstructured":"Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. 1998;50:1746\u20139.","journal-title":"Neurology"},{"key":"721_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539\u201348.","journal-title":"Genet Med"},{"issue":"Suppl A","key":"721_CR8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0149-2918(07)80115-9","volume":"29","author":"C Wanner","year":"2007","unstructured":"Wanner C. Fabry disease model: a rational approach to the management of Fabry disease. Clin Ther. 2007;29 Suppl A:S2\u20135.","journal-title":"Clin Ther"},{"key":"721_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1161\/01.STR.32.7.1559","volume":"32","author":"G Altarescu","year":"2001","unstructured":"Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke. 2001;32:1559\u201362.","journal-title":"Stroke"},{"key":"721_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","volume":"47","author":"T DeGraba","year":"2000","unstructured":"DeGraba T, Azhar S, Dignat-George F, Brown E, Bouti\u00e8re B, Altarescu G, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229\u201333.","journal-title":"Ann Neurol"},{"key":"721_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1447-0756.1985.tb00045.x","volume":"11","author":"O Tsutsumi","year":"1985","unstructured":"Tsutsumi O, Sato M, Sato K, Sato K, Mizuno M, Sakamoto S. Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry\u2019s disease. Asia Ocean J Obstet Gynaecol. 1985;11:39\u201345.","journal-title":"Asia Ocean J Obstet Gynaecol"},{"key":"721_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","volume":"29","author":"AC Vedder","year":"2006","unstructured":"Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JMFG, Hollak CEM. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis. 2006;29:106\u201311.","journal-title":"J Inherit Metab Dis"},{"key":"721_CR13","doi-asserted-by":"crossref","unstructured":"Shayman JA, Killen PD. Fabry disease. In: Molecular and genetic basis of renal disease. Philadelphia Saunders: Elsevier; 2008. p. 195\u20139.","DOI":"10.1016\/B978-1-4160-0252-9.50017-3"},{"key":"721_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19:782\u20137.","journal-title":"Am J Hypertens"},{"key":"721_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/ATVBAHA.113.302200","volume":"34","author":"S Choi","year":"2014","unstructured":"Choi S, Kim JA, Na H-Y, de Lorenzo AG, Ricci R, Kampmann C, et al. Globotriaosylceramide induces lysosomal degradation of endothelial K Ca 3.1 in Fabry disease. Arterioscler Thromb Vasc Biol. 2014;34:81\u201389.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"721_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/ATVBAHA.113.302744","volume":"34","author":"K Satoh","year":"2014","unstructured":"Satoh K. Globotriaosylceramide induces endothelial dysfunction in fabry disease. Arterioscler Thromb Vasc Biol. 2014;34:2\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"721_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/8904_2012_177","volume":"9","author":"A Pisani","year":"2013","unstructured":"Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, et al. Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. JIMD Rep. 2013;9:41\u20138.","journal-title":"JIMD Rep"},{"key":"721_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"721_CR19","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin V, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454.","journal-title":"Mol Genet Metab Rep"},{"key":"721_CR20","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/01.CIR.99.18.2434","volume":"99","author":"J Blacher","year":"1999","unstructured":"Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434\u20139.","journal-title":"Circulation"},{"key":"721_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10545-011-9428-z","volume":"35","author":"K Nicholls","year":"2012","unstructured":"Nicholls K. Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients. J Inherit Metab Dis. 2012;35:885\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"721_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYP.0000000000000033","volume":"66","author":"RR Townsend","year":"2015","unstructured":"Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension. 2015;66:698\u2013722.","journal-title":"Hypertension"},{"key":"721_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353\u20138.","journal-title":"J Med Genet"},{"key":"721_CR24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","volume":"38","author":"R Schiffmann","year":"2015","unstructured":"Schiffmann R, Swift C, Wang X, Blankenship D, Ries M. A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease. J Inherit Metab Dis. 2015;38:1129\u201336.","journal-title":"J Inherit Metab Dis"},{"key":"721_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF03401671","volume":"3","author":"CM Eng","year":"1997","unstructured":"Eng CM, Ashley GA, Burgert TS, Enriquez AL, D\u2019Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med. 1997;3:174\u201382.","journal-title":"Mol Med"},{"key":"721_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CEM, Poorthuis BJHM. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015;52:262\u20138.","journal-title":"J Med Genet"},{"key":"721_CR27","doi-asserted-by":"publisher","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One. 2017;12:e0173358.","journal-title":"PLoS One"},{"key":"721_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.anorl.2019.04.014","volume":"136","author":"C Eyermann","year":"2019","unstructured":"Eyermann C, Raguin T, Rohmer D, Noel E, Charpiot A. Cochleovestibular manifestations in Fabry disease: Importance of screening and systematic ENT evaluation. Eur Ann Otorhinolaryngol Head Neck Dis. 2019;136:273\u20139.","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"721_CR29","unstructured":"Schiffmann R, Moore DF. Neurological effects of enzyme replacement therapy in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis: Oxford; 2006. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11595\/. Accessed 14 Jan 2020."},{"key":"721_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"721_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0021-9150(03)00097-2","volume":"170","author":"S Blankenberg","year":"2003","unstructured":"Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191\u2013203.","journal-title":"Atherosclerosis"},{"key":"721_CR32","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1681\/ASN.2007030312","volume":"18","author":"DG Warnock","year":"2007","unstructured":"Warnock DG. Enzyme replacement therapy and Fabry kidney disease: quo vadis? J Am Soc Nephrol. 2007;18:1368\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"721_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","volume":"60","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, van den Bogaard B, de Groot E, Groener JEM, Poorthuis BJ, Linthorst GE, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension. 2012;60:998\u20131005.","journal-title":"Hypertension"},{"key":"721_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2369-15-72","volume":"15","author":"S Waldek","year":"2014","unstructured":"Waldek S, Feriozzi S. Fabry nephropathy: a review\u2014how can we optimize the management of Fabry nephropathy? BMC Nephrol. 2014;15:72.","journal-title":"BMC Nephrol"},{"key":"721_CR35","doi-asserted-by":"publisher","first-page":"e12914","DOI":"10.1111\/ijcp.12914","volume":"71","author":"R Reisin","year":"2017","unstructured":"Reisin R, Perrin A, Garc\u00eda-Pav\u00eda P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pr. 2017;71:e12914.","journal-title":"Int J Clin Pr"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-020-00721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-020-00721-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-020-00721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T23:24:38Z","timestamp":1631921078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-020-00721-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1038\/s41431-020-00721-9","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"type":"print","value":"1018-4813"},{"type":"electronic","value":"1476-5438"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors consent to the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}